In general, L-cysteine and D-penicillamine form similar types of complexes with transition metal ions. However, in certain cases, the subtle differences in the properties of the ligands result in significant reaction differences, particularly when applied to redox systems of transition metals. For example, this difference in behaviour has been used in the mobilization of copper in the treatment of Wilson's disease with Dpenicillamine, and also in the treatment of gold toxicity in patients having gold therapy. Although considerable work has been done on the chemistry of copper (I) and (II) with D-penicillamine, little has been published on penicillamine reactions with gold.
Both L-cysteine and D-penicillamine are optically active, and thus form optically active complexes with gold. These generally show welldefined Cotton effects. In the complexes examined, gold (I) complexed to at least one sulphur ligand shows Cotton effects below 400 nm, whereas gold (III) complexes show at least two Cotton effects between 400 and 530 nm. These results are based on the Cotton effects of solid complexes of known composition.
L-cysteine in aqueous solution reduces gold (III) to gold (I) and forms a stable gold (I) complex. This reaction is typical of most thiols, e.g. thiomalic acid and thioglucose react similarly. When L-cysteine is added to a solution of the Au(CN)2-ion in water, the stable gold (I) cysteine complex is formed. Finely divided gold metal reacts slowly in the presence of oxygen with Lcysteine, again to give the gold (I) cysteine complex.
D-penicillamine, on the other hand, when added in excess to gold (III) solutions, forms a gold (III) complex. If the ratio of D-penicillamine to gold falls to about 1:1, the complex decomposes, going through an unstable gold (I) complex stage and finishing up as gold metal. With a range of water soluble gold (I) complexes in the presence of excess D-penicillamine, air oxidation occurs, and gold (III) penicillamine complexes are formed. Among the gold (I) complexes examined were the thiomalate, thioglucose, and thiosulphate complexes which are used in the treatment of rheumatoid arthritis. We have shown that part of the gold bound to the albumin of patients under gold therapy is present as loosely bound gold (I) thiomalate which can be separated by electrophoresis and which is susceptible to chemical attack. Thus it seems likely that, in the presence of excess D-penicillamine, part of the protein-bound gold will be labilized. As with L-Cysteine, finely divided gold reacts slowly with D-penicillamine in air, although in this case, the product is a watersoluble gold (III) D-penicillamine complex.
It is difficult to extrapolate results in vitro to in vivo, but the above results suggest that Dpenicillamine is unlikely to be useful in removing all the gold from patients suffering from gold toxicity because it would be difficult to keep the concentration consistently high enough. Thus, although some gold will be removed as gold (III) penicillamine, the major effect will be a redistribution of gold within the body. Whether this in itself could be useful will depend on further information being gained on the cause of gold toxicity. He has talked about the possible use of penicillamine in the treatment of gold toxicity. Dr Jaffe and I have wondered in the past whether a combination of gold and penicillamine might be a synergistically better treatment for rheumatoid arthritis than either alone.
DISCUSSION
Dr Brown: The evidence, such as it is, that is accumulating in the literature, suggests that the nature of the ligand attached to gold is important. If penicillamine is added with gold I would expect that there would be a different distribution of gold in the body from that which occurs when gold thiomalate is added. Experiment can tell which is better. Dr B P Swann (Windlesham): Has Dr Brown any evidence for the structure of the penicillamine gold (III) complex that he mentioned, in terms of interpreting the fact that it does not get reduced to gold (I) ?
Dr Brown: As far as we can see, we have isolated two or three solids, D-penicillamine gold (III) solids, but we do not know whether the solid obtained is the same as the material that is in solution. It appears to be a polymeric species which comes out of solution. They seem to be square planar complexes with chelating penicillamine, certainly through the sulphur and possibly through the carboxylic acid, but we have to check up on that.
Dr Swann: Are they crystalline, in the sense that X-ray crystal structures could be obtained from them? Dr Brown: As far as we can tell, the gold is distributed and carried round the body mainly in the various odd proteins in the blood serum, but it depends on the patient and is not something I should like to quantify. We have studied a number of patients, and many of the rheumatoid patients have varying concentrations of the different proteins present in the blood serum. Albumin obviously carries the major amount, but quite a few of the other proteins also contain some gold. These appear to be partly gold thiomalate protein and partly gold protein.
We also have some evidence of the presence of gold in white blood cells, and also in the various phagocytic cells. I am not sure what this means and we have not studied these in detail. Our next stage will be trying to investigate the chemistry.
